Which one is better, dasatinib or nilotinib?

Dasatinib and nilotinib are both prescription drugs used to treat chronic myelogenous leukemia, a type of blood cancer. Dasatinib is also approved for other types of cancers and tumors. These drugs are all classified as BCR-ABL kinase inhibitors and have a similar mechanism of action, blocking the BCR-ABL tyrosine kinase, an important pathway in the development of leukemia.

Leukemia is a type of blood cancer that usually starts in white blood cells. Leukemia can be fast-growing (acute) or slower-growing (chronic). Some leukemias are called Philadelphia positive (Ph+). The BCR-ABL fusion gene (Philadelphia chromosome) is commonly found in patients with chronic myelogenous leukemia (CML) and some patients with acute lymphoblastic leukemia (ALL). Tyrosine kinases are involved in many cellular functions, including cell communication, cell maturation, and cell division. Blocking these enzymes may help slow the growth of cancer in leukemia. The choice of these two drugs should be determined based on the patient's specific situation and the recommendations of the doctor. Some patients are more sensitive to one of the drugs, while others are more sensitive to the other.

The original drug of dasatinib has been launched in China and is included in the medical insurance. Currently, reimbursement is only available to eligible patients. Common specifications The price of each box of 50mg*60 tablets may be around RMB 10,000. The original drug overseas is even more expensive. Dasatinib generics are also sold overseas. The ingredients of the drug are basically the same as those sold domestically and abroad, but the price is cheap. For example, the price of a box of 50mg*60 tablets produced by an Indian pharmaceutical factory may be several hundred yuan (the price may fluctuate due to exchange rates).